CytomX Therapeutics

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Earnings data Q4 2022

Earnings data Q1 2023

SOUTH SAN FRANCISCO, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it will report full year 2022 financial results on Monday, March 27, 2023, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.

CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in the following investor conferences in March.

CytomX Therapeutics to Present at Upcoming March Investor Conferences

-Achievement of clinical candidate is the first in the multi-target collaboration and triggers a $5 million milestone payment to CytomX-

CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

SOUTH SAN FRANCISCO, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present at the B. Riley Securities Virtual Annual Oncology Investor Conference on Thursday, January 19, 2023 at 2:30 p.m. ET.

CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Investor Conference

Geron

Zomedica

Are you using these tips for investing in penny stocks? The post How to Start Investing in Penny Stocks in 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Start Investing in Penny Stocks in 2023

Moderna

CytomX (CTMX) inks an agreement with Moderna to develop therapeutics for oncology and non-oncology conditions. The company also provides its business outlook for 2023.

CytomX (CTMX) Up 55% on Strategic Partnership With Moderna

On a resoundingly positive Friday for the market, CytomX Therapeutics (NASDAQ: CTMX ) is providing a large portion of the fireworks. Specifically, CTMX stock skyrocketed more than 50% before settling at a 40% increase as of this writing.

CytomX Therapeutics (CTMX) Stock Jumps 50% on Moderna Deal

CytomX Therapeutics Inc. CTMX, +7.19% shares soared more than 50% in the extended session Thursday after the small biotech company announced a partnership with Moderna Inc. MRNA, -2.17% CytomX shares were last up 57% after hours, following a 7.2% rise to close the regular session at $1.79. Under the agreement, CytomX gets a $35 million up-front payment, and is eligible for up to $1.2 billion in additional payments to research and develop “messenger RNA-based conditionally activated therapeutics” with Moderna.

CytomX shares surge more than 50% on Moderna partnership

Moderna Inc on Thursday announced a $35 million licensing deal with cancer-focused drug developer CytomX Therapeutics to work on messenger RNA-based therapies for a wide range of diseases.

Moderna signs $35 million deal with cancer drug developer CytomX

Collaboration will combine Moderna's mRNA technology with CytomX's Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditions CytomX to receive $35 million upfront payment with the potential for additional research, milestone, and royalty payments CAMBRIDGE, MA and SOUTH SAN FRANCISCO, CA / ACCESSWIRE / January 5, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies utilizing Moderna's mRNA technologies and CytomX's Probody® therapeutic platform. The research collaboration will leverage core scientific advances at Moderna and CytomX.

Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

Collaboration will combine Moderna's mRNA technology with CytomX's Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditions

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

- CX-2029 (CD71 conditionally activated ADC) continued to demonstrate encouraging anti-cancer activity in squamous tumors in the now completed Phase 2 Cohort Expansion Study. AbbVie and CytomX to determine next steps for program in 2023 -

CytomX Therapeutics Provides Business Update and Outlines 2023 Company Priorities

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it plans to outline its pipeline priorities for 2023 and provide a data update for the CX-2029 Phase 2 cohort expansion study, on Thursday, January 5, 2023, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss updates.

CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 3:00 p.m. ET.

CytomX Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) --  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Phase 2 data for CX-2009, a conditionally activated antibody drug conjugate (ADC) targeting CD166, will be presented at the San Antonio Breast Cancer Symposium on December 8th. The poster details the results from patients treated with monotherapy praluzatamab ravtansine for the treatment of advanced HR+/HER2- breast cancer and triple negative breast cancer (TNBC).

CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine (CX-2009) in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium

Ensysce Biosciences

NeuroOne Medical Technologies Corp

Nexalin Technology Inc

Taysha Gene Therapies

Biotech penny stocks to watch this week. Are they a buy now?

Best Penny Stocks To Buy Now? 5 Biotech Stocks To Watch This Week

CytomX (CTMX) gets a boost after its deal with Regeneron for the development of investigational next-generation bispecific immunotherapies.

CytomX (CTMX) Stock Surges on Oncology Deal With Regeneron

CytomX Therapeutics (NASDAQ: CTMX ) stock is rising higher on Wednesday after announcing a partnership with Regeneron Pharmaceuticals (NASDAQ: REGN ). This strategic partnership will see the two companies working together on the development of cancer therapies.

Why Is CytomX Therapeutics (CTMX) Stock Up 29% Today?

- Collaboration will enable the development of investigational next-generation bispecific immunotherapies using CytomX's Probody ® and Regeneron's Veloci-Bi ® platforms -

CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

Regeneron Pharmaceuticals

Collaboration will enable the development of investigational next-generation bispecific immunotherapies using CytomX's Probody® and Regeneron's Veloci-Bi ® platforms CytomX to receive $30 million upfront payment with the potential for up to $2 billion in research, development, regulatory and sales-based milestones TARRYTOWN, N.Y. and SOUTH SAN FRANCISCO, Calif.

Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Chris Ogden - SVP of Finance and Accounting Sean McCarthy - CEO and Chairman Conference Call Participants Peter Lawson - Barclays Etzer Darout - BMO Capital Markets Mara Goldstein - Mizuho Group Mitchell Kapoor - H.C. Wainwright Joseph Catanzaro - Piper Operator Good day, and thank you for standing by.

CytomX Therapeutics, Inc. (CTMX) Q3 2022 Earnings Call Transcript

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -9.38% and 9.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CytomX Therapeutics (CTMX) Reports Q3 Loss, Misses Revenue Estimates

- Advancing wholly owned, next-generation conditionally activated therapeutics CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b), with INDs anticipated in 2023 -

CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

- IND filing for CX-801 is anticipated in the second half of 2023 - - IND filing for CX-801 is anticipated in the second half of 2023 -

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b (CX-801) at the SITC 2022 Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in the following investor conferences in November.

News for CytomX Therapeutics Stock (CTMX)